Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Sep 08, 2026
CRCG: +105% in 30 Days as CRCL Rallies – Inside the 2X Leveraged ETF

CRCG: +105% in 30 Days as CRCL Rallies – Inside the 2X Leveraged ETF

Key Takeaways

  • CRCG is a single-stock leveraged exchange-traded fund (ETF) that seeks to deliver twice (2x) the daily return of Circle Internet Group (CRCL), the issuer of the USD Coin (USDC) stablecoin.
  • The fund has gained roughly 105% over the trailing 30 days, recovering from its late-July and early-August lows.
  • Despite the sharp rebound, CRCG remains down approximately 40% over the trailing quarter, reflecting Circle's broader 2026 drawdown.
  • The recent move was driven primarily by a rally in CRCL shares tied to crypto-market momentum and regulatory developments, magnified by the fund's 2x leverage.
  • As a daily-reset leveraged product, CRCG is intended for short-term trading and carries elevated volatility-decay and compounding risk.

Understanding CRCG and Its Exposure to CRCL

CRCG is an actively managed, single-stock leveraged ETF that targets 200% of the daily performance of Circle Internet Group, a financial-technology company best known for issuing USDC, the second-largest dollar-pegged stablecoin by market value. The fund pursues its objective through total-return swap agreements with multiple counterparties rather than by holding CRCL shares directly, with short-term Treasury obligations serving as collateral.

The fund has a total expense ratio of approximately 0.75% and held roughly $67 million in assets under management (AUM) as of mid-2026, having launched in August 2025. Its concentrated, single-name structure means its price behavior is almost entirely a leveraged expression of CRCL's own volatility, with limited diversification to offset single-stock risk. I also checked this using Tickeron’s AI Screener to see how the fund stacks up against other thematic leveraged products.

CRCG Price Performance: The Last 30 Days Compared With the Quarter

Over the trailing 30 days, CRCG has surged about 105%, climbing from a closing price near $8.05 to roughly $16.52. The advance was anything but gradual: the fund traded as low as about $7.42 in early August before a powerful, momentum-driven rebound carried it sharply higher through the second half of the month.

The broader picture is more sobering. Measured over the trailing quarter, the fund remains down approximately 40%, falling from a level near $27 in late May. This divergence between the 30-day rebound and the negative quarterly trend underscores how leverage converts short-term rallies into outsized moves without erasing the cumulative losses of a sustained decline.

What Fueled the Recent 30-Day Rebound

The fund's rebound was a direct, leveraged reflection of strength in Circle's underlying shares. After testing a support level near $59 through July and early August, CRCL rallied decisively, advancing into the low $90s by late August. Because CRCG targets 2x the daily move, each percentage gain in the underlying stock translated into a proportionally larger move in the ETF.

Several catalysts fueled the underlying rally. The Securities and Exchange Commission (SEC) proposed a framework that would allow certain crypto projects to raise up to $75 million without full securities registration, while the Financial Accounting Standards Board (FASB) proposed treating qualifying stablecoins as cash equivalents. A White House meeting with crypto-industry executives, a renewed rise in Bitcoin above $70,000, and reported weekly USDC supply growth of about $1.7 billion after a period of stagnation added to the momentum. Analyst firms also raised price targets on Circle, with one setting a $140 target and another lifting its target to $92.

Why the Quarterly Performance Lagged

The negative quarterly trend reflects a longer period of pressure on Circle shares, which fell more than 70% from their all-time high amid a broader crypto-market downturn. Circle's second-quarter results, while profitable, missed revenue expectations as reserve income remained dependent on prevailing interest rates, with the reserve yield declining year over year. Competitive concerns also weighed on sentiment after a consortium of companies announced a rival stablecoin initiative.

For a leveraged product, these underlying declines were compounded. The fund's 2x daily exposure and daily reset mechanism meant that a sequence of negative days in the underlying stock produced deeper cumulative losses than a simple 2x multiple of the underlying's total decline would suggest, a structural feature common to daily-leveraged instruments.

Key Factors to Watch for CRCG Going Forward

Several factors are likely to influence CRCG over the coming months, given its direct link to Circle and its leveraged structure. The Digital Asset Market Clarity Act (CLARITY Act), a market-structure bill with a Senate vote expected in September, remains a focal point, as does the planned mainnet launch of Circle's Arc blockchain network. Circle's recently granted national trust bank charter could also expand its custody and tokenization capabilities over time.

Investors should monitor reserve-income sensitivity to interest rates, competition from rival stablecoin issuers and distribution platforms such as Coinbase, and the broader crypto-market risk environment that historically drives Circle's valuation. Most importantly, the fund's daily rebalancing and 2x leverage make it inherently unsuitable for buy-and-hold positions over extended periods, as volatility decay and compounding can erode returns even when the underlying stock recovers. No price predictions are warranted, but the dominant themes are regulatory clarity, USDC adoption, crypto-market sentiment, and the structural risks unique to leveraged single-stock ETFs.

Using Tickeron’s AI Screener for Leveraged ETF Research

In my own work, Tickeron’s AI Screener has become a practical way to quickly filter through thousands of securities with technical indicators, fundamentals, volatility metrics, price patterns, and AI-generated signals. It lets me apply custom criteria to surface leveraged or thematic products like CRCG without reviewing each candidate individually. The platform helps make the research process more efficient whether I am focused on short-term trading ideas or longer-term themes. Explore the AI Screener to see how it aligns with your own approach.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CRCG

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


CRCG's Stochastic Oscillator stays in oversold zone for 3 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +22.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRCG advanced for three days, in 36 of 43 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

CRCG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 22 of 33 cases where CRCG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.

Bearish Trend Analysis

The 10-day RSI Indicator for CRCG moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 2 similar instances where the indicator moved out of overbought territory. In 2 of the 2 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRCG as a result. In 21 of 21 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for CRCG turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 7 similar instances when the indicator turned negative. In 6 of the 7 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

CRCG moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRCG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Industry description

The investment seeks daily levered investment results, before fees and expenses, of two times (200%) of the daily percentage change in the price of the common stock of CRCL. The fund is an actively managed ETF. The fund invests at least 80% of its net assets (plus borrowings for investment purposes) in financial instruments with economic characteristics that, in combination, provide 200% daily leveraged exposure to the price of CRCL, consistent with the fund’s investment objective. The fund is non-diversified.
View a ticker or compare two or three
CRCG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
United States
Phone
N/A
Web
www.ThemesETFs.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.